Protein self-assembly based NIR-responsive photodynamic- angiogenic multifunctional therapeutic formulation for the chronic wound healing

IN598187BActive Publication Date: 2026-08-06INDIAN INSTITUTE OF TECHNOLOGY JODHPUR
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202411052798
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2026-08-06
Estimated Expiration
2044-07-10

AI Technical Summary

Technical Problem

Current treatments for chronic wounds, particularly diabetic foot ulcers, are limited in effectiveness, costly, and lack a comprehensive solution that can simultaneously kill bacteria, promote angiogenesis, and address hypoalbuminemia.

Method used

A self-assembled structure of Cu²⁺-induced bovine serum albumin (BSA)-Indocyanine green (ICG) complex, which generates reactive oxygen species (ROS) under NIR laser exposure, releases Cu²⁺ for angiogenesis, and increases interstitial albumin content, formed under specific conditions to ensure biocompatibility and efficacy.

Benefits of technology

The formulation effectively kills bacteria, including antibiotic-resistant strains, promotes new blood vessel formation, and enhances wound healing by increasing albumin levels, providing a cost-effective, biocompatible, and biodegradable treatment for chronic wounds.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A protein based multifunctional therapeutics suitable for chronic wound healing including diabetic foot ulcers (DFU) comprises a self-assembled structure of ‘d’ block bivalent metal ion induced serum albumin and NIR photosensitizer complex having co-acting NIR responsive photodynamic and angiogenic wound healing capability; wherein said ‘d’ block bivalent metal ion is selected from Cu+2……. , serum albumin is selected from bovine serum albumin albumin of other origin with a minimum of 70% homology in amino acid sequence with bovine serum albumin and said NIR photosensitizer is selected from Indocyanine green(ICG) or its derivatives…….. The complex comprises serum albumin-ICG-Cu (II) in molar ratio of 1:1:6. said Cu+2 ion induced self-assembled aggregates of serum albumin-ICG-Cu+2 complex is bindable with florescent probes including 8-anilino-1-naphthalenesulfonic acid (ANS), for fluorescing in hydrophobic pockets. Fig. 1
Need to check novelty before this filing date? Find Prior Art

Description

DESC:Field of the Invention The present invention is directed to a photodynamic- angiogenic multifunctional therapeutic formulation for the chronic wound healing. More specifically the present invention is directed to a Copper (II) ion induced bovine serum albumin (BSA)-Indocyanine green(ICG) molecular self-assembly as the photodynamic- angiogenic multifunctional therapeutic formulation for the management of chronic wounds including but not limited to diabetic foot ulcer (DFU)and its preparation following green chemistry approach. Advantageously the present invention is a 3-in-1 solution for (i) killing bacteria present in the wound milieu by photodynamic effect, (ii) ensuring new blood vessel formation and (iii) protecting the neo-granulating tissue from MMPs. It is biocompatible and made with FDA approved materials.Background of the InventionDiabetic foot ulcers (DFUs) are the fastest growing chronic complication of diabetes mellitus and in many cases, it needs surgical intervention and foot amputation. Treatment of DFU is of paramount importance. Unfortunately, DFU is hard to treat through the existing therapeutic modalities because of the multiple challenges associated with the pathobiology of chronic wound. The unmet need in this regard is the lack of availability of effective therapeutics that can heal the chronic wound. There are plenty of literature available that has highlighted the existing challenges associated with diabetic foot ulcer and lack of effective therapeutics for the same.For the treatment of wound tissues with bacterial infection, Chen B et al. have fabricated a hollow channeled hydrogel scaffold based on the mixture of dopamine modified alginate (Alg-DA) and gelatin via co-axial 3D printing (Biomedical Materials. 2023 May 26). The scaffold was crosslinked by copper / calcium ions, and copper ions crosslinking endowed the scaffold with good photothermal effects. The photothermal effect and copper ions showed excellent antibacterial activity against both Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria. Moreover, the hollow channels and the sustained released copper ions could stimulate angiogenesis and accelerate wound healing process. Bacterial overgrowth in injured wounds causes wound infection and excessive inflammation, leading to delayed wound healing. In an effort to heal infected wounds, bacterial cellulose (BC) deposited with Cu2+-loaded phase-transited lysozyme (PTL) nanofilm (BC / PTL / Cu) was prepared wherein Cu2+ was loaded into PTL through electrostatic coordination (He W. et al., Carbohydrate Polymers. 2023 Jun 1;309:120681). Said BC / PTL / Cu displayed slower release rate of Cu2+ compared with BC directly loaded with Cu2+ and exhibited good antibacterial activity against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, and Pseudomonas aeruginosa. In vivo, BC / PTL / Cu accelerated wound healing and promoted re-epithelialization, collagen deposition, and angiogenesis while inhibiting inflammation of the infected full-thickness skin wounds of rats. For controlled and triggered release of drugs depending on the wound microenvironment metformin-laden CuPDA NPs composite hydrogel (Met@ CuPDA NPs / HG) was fabricated by dynamic phenylborate bonding of gelatin modified by dopamine (Gel-DA), Cu-loaded polydopamine nanoparticles (CuPDA NPs) with hyaluronic acid modified by phenyl boronate acid (HA-PBA), which possesses good injectability, pH and glucose responsive slow release, self-healing, adhesive and DPPH scavenging performance (Zhu S. et al.; Bioactive Materials. 2023 Aug 1). Animal experiments demonstrated that Met@CuPDA NPs / HG significantly promoted wound healing of diabetic SD rats by killing bacteria, inhibiting inflammation, improving angiogenesis and accelerating the deposition of ECM and collagen. Wang Y et al. (Polymer Testing. 2022 Dec 1;116:107762) developed a near-infrared (NIR) light-activated PLGA microsphere loaded with two kinds of drugs with different molecular weights respectively or simultaneously by the double emulsion method (bovine serum albumin (BSA) and tetracycline hydrochloride (TH) as the drug model agents, indocyanine green (ICG) as the NIR responsive component). The spherical PLGA microspheres having diameter ranging from 5 to 10 µm exhibited desirable biodegradability, low cytotoxicity and with EE (Encapsulation efficiency) of ICG, BSA, and TH 83.37 ± 0.59%, 52.65 ± 3.48%, and 12.88 ± 2.53% respectively. All the NIR-responsive PLGA microspheres exhibited an efficient photothermal property and enhanced photothermal stability under multiple NIR irradiation cycles. The drugs from the different PLGA microspheres were released continuously over 18 days.Xu et al., 2022 (ACS Omega, 7(38), 33821–33829) designed a new antibacterial nanoagent comprising, a photosensitizer (indocyanine green, ICG) and bovine serum albumin (BSA) wherein ICG was loaded in BSA which undergo hydrophobic-interaction-induced self-assembly to form stable BSA@ICG nanoparticles. Furthermore, a positively charged antibacterial peptide bacitracin (Bac) was physically immobilized onto the surface of BSA@ICG to generate a bacterial-targeted nanomedicine BSA@ICG@Bac through electrostatic interactions. The obtained BSA@ICG@Bac showed both good singlet oxygen generation property and high photothermal conversion efficiency. In addition, it showed enhanced photodynamic and photothermal antibacterial capacities and biofilm-removing ability in vitro due to Bac modification. Lee Wt et al.(2007,Journal of Inorganic Biochemistry, 101(11–12), 1707–1718)fabricated an in situ-injectable PEG hydrogel system prepared with (i) nabTM-technique-based paclitaxel (PTX)-bound albumin nanoparticles with chlorin-e6 (Ce6)-conjugated bovine serum albumin (BSA-Ce6) and indocyanine green (ICG), named ICG / PTX / BSA-Ce6-NPs (~175 nm), and (ii) an albumin-stabilized perfluorocarbon (PFC) nano-emulsion (BSA-PFC-NEs; ~320 nm) for combined therapy involving photothermal and photodynamic treatments together with chemotherapeutic agents (Pharmaceutics. 2022 Jan 8; 14(1):148). This multifunctional PEG hydrogel displayed significantly enhanced killing of three-dimensional 4T1 cell spheroids and suppressed the growth of xenografted 4T1 cell tumors in mice (tumor volume: 47.7 ± 11.6 and 63.4 ± 13.0 mm3 for photothermal and photodynamic treatment, respectively, vs. PBS group (805.9 ± 138.5 mm3). The PEG hydrogel formula also showed excellent hyperthermal efficacy (>50 °C), ablating the 4T1 tumors when the irradiation duration was extended, and output intensity was increased. An antibacterial wound dressings G-BSA-Ag was produced by integrating the Bovine serum albumin (BSA) fibrous films with glycerol and decorated with silver (Zhang F et al.; Chemical Engineering Journal. 2021 Aug 1; 417:129145). The as-synthesized G-BSA-Ag films combined the antibacterial properties of silver, the biocompatibility of BSA and the wettability of glycerol. The in vitro and in vivo biocompatibility analysis of G-BSA-Ag films confirmed their non-hemolysis, durable antibacterial properties, non-cytotoxicity, and promotion to cell migration. Application of the G-BSA-Ag films on a S. aureus-infected mouse wound model, showed accelerated healing rate with reduced inflammatory factor levels. Indocyanine green (ICG) is a favorable fluorescence nanoprobe for its strong NIR-I fluorescence emission and good photothermal capabilities. However, the stability and tumor targeting ability of ICG is poor, which limits its applications. To improve the photothermal and therapeutic efficiency of ICG, bovine serum albumin (BSA) was utilized to encapsulate the ICG and the chemotherapeutic drug doxorubicin (DOX) was loaded to form the BSA@ICG-DOX theranostic nanoplatform (Ma, R. et al.; International Journal of Nanomedicine. 2021 Jul 17:4847-61). The BSA@ICG-DOX NPs were spherical with an average size of ~194.7 nm and were fabricated using reprecipitation methods. The NPs had high encapsulation efficiency (DOX: 19.96% and ICG: 60.57%), and drug loading content (DOX: 0.95% and ICG: 3.03%). The NIR excitation / emission and targeted BSA@ICG-DOX NPs enables high-performance diagnosis and chemo / photothermal therapy of subcutaneous cervical tumors. The prior art (Liu J et al.; ACS Applied Materials & Interfaces. 2021 Feb 5;13(6):7115-26) relates to a combination cancer treatment with minimal side effects in clinical applications and provides a trifunctional layered double hydroxide (LDH) nanosystem for combined photo-chemotherapy of skin cancer at very low therapeutic doses. This nanosystem (ICG / Cu-LDH@BSA-DOX) is composed of acid-responsive bovine serum albumin-doxorubicin prodrug (BSA-DOX) and indocyanine green (ICG)-intercalated Cu-doped LDH nanoparticle. ICG / Cu-LDH@BSA-DOX is able to release DOX in an acid-triggered manner, efficiently and simultaneously generates heating and reactive oxygen species (ROS) upon laser irradiation, and induces apoptosis of skin cancer cells. In vivo therapeutic evaluations demonstrate that ICG / Cu-LDH@BSA-DOX nearly eradicated the tumor tissues upon one-course treatment using very low doses of therapeutic agents and very mild 808 nm laser irradiation (0.3 W / cm2 for 2 min). A multifunctional integrally medicalized hydrogel BSA@Gelatin-Cu2+-REG, is developed using bovine serum albumin (BSA) and gelatin crosslinked via copper sulfate (Cu2+) with a thiol group (-SH), as an injectable scaffold loading the functional peptide REGRT (REG), which considerably accelerated vascularization and tissue regeneration (Zhang L. et al.; Chemical Engineering Journal. 2021 Feb 15; 406:126839). The easily biodegradable BSA and gelatin provide an appropriate drug release rate and promote cell adhesion. The prepared hydrogel BSA@Gelatin-Cu2+-REG possessed internal synergy and acted as a thruster for rapid angiogenesis and tissue regeneration. Glycation of proteins has found promising applications in wound healing wherein a simple conjugation process was employed to develop bovine serum albumin–dextran conjugates (BSA–dextran) using Maillard reaction (Rohiwal SS et al.; RSC advances. 2021;11(8):4308-17). A marked increase in percentage of radical scavenging activity of the conjugates makes it an effective antioxidant synthetic strategy. Higher electrophoretic mobility and surface charge in the prepared conjugates was observed in native PAGE electrophoresis and zeta potential. Moreover, the fluorescence, FTIR and Raman analysis of the BSA–dextran conjugates shows significant shift in the fluorescence and wavelength as a consequence of conjugate formation. In vitro wound healing assay showed increased cell proliferation and migration effect, however no in vivo studies were provided.To evaluate the efficacy and safety of a novel spray-applied growth factor therapy (Park KH et al.; Diabetes research and clinical practice. 2018 Aug 1;142:335-44) containing recombinant human epidermal growth factor (rhEGF) for the treatment of chronic diabetic foot ulcers (DFU) a phase III double-blind, randomized, placebo-controlled trial was conducted involving 167 adult patients. More patients in the rhEGF group significantly had complete wound healing compared to placebo (73.2% versus 50.6%, respectively; P = .001). This study confirms that application of spray-applied rhEGF in DFU patients results in faster healing velocity and higher complete healing rate regardless of HbA1c levels.A Bioglass / albumin composite hydrogel with controllable injectability, good adhesiveness, and bioactivity, is developed by utilizing dual-functional bioactive ions released from Bioglass, which on one side controls the gelling time by creating an alkaline environment to regulate the cross-linking reaction between human serum albumin and succinimidyl succinate modified poly(ethylene glycol), and on the other side stimulates wound healing. The in vivo experiment confirms that this composite hydrogel has good bioactivity to stimulate angiogenesis and enhance chronic wound healing (Zhou Y, et al.; Advanced healthcare materials. 2018 Aug; 7(16):1800144)A phototherapy nanoplatform prepared (Han L, et al.; Journal of materials chemistry B. 2016;4(1):105-12) by coating hollow CuS nanoparticles with a bovine serum albumin–folic acid (BSA–FA) complex to establish a combined therapy consisting of photothermal therapy (by CuS–BSA–FA nanocarriers) and cytotoxic effects of photodynamic and photothermal therapy (by ICG upon 808 nm laser irradiation. The obtained CuS–BSA–FA nanoparticles are used as drug-delivery vehicles to transport a near-infrared-absorbing phototherapeutic agent (indocyanine green, ICG) into HeLa cells, after loading ICG onto CuS–BSA–FA. The encapsulation of ICG onto CuS–BSA–FA significantly improves the stability and reduces the dark toxicity of free ICG. This therapeutic system exhibits an higher photothermal heating effect and capability of 1O2 generation under laser irradiation compared with bare nanocarriers. A programmed assembly strategy was developed for the preparation of human serum albumin (HSA)-indocyanine green (ICG) nanoparticles (HSA-ICG NPs) by intermolecular disulfide conjugations (Sheng Z et al.; ACS nano. 2014 Dec 23;8(12):12310-22). After an intravenous injection of HSA-ICG NPs followed by imaging-guided precision phototherapy (808 nm, 0.8 W / cm2 for 5 min), the tumor was completely suppressed, no tumor recurrence and treatments-induced toxicity were observed. The results suggest that HSA-ICG NPs generated by programmed assembly as smart theranostic nanoplatforms are highly potential for imaging-guided cancer phototherapy with PDT / PTT synergistic effects.Wound healing is often impaired by hypoalbuminemia, and therefore albumin has traditionally been administered to derive beneficial effects on general physiologic conditions including the nutritional state. However, the influence of albumin administration on systemic protein metabolism and wound healing is still unclear. Therefore, the aim of Kobayashi N. et al was to investigate the influence of albumin administration on protein metabolism and wound healing in burned rats (Kobayashi N. et al.; Wound repair and regeneration. 2004 Jan;12(1):109-14). In vivo studies revealed that Hydroxyproline levels, and both protein synthesis (S) and breakdown (B) in the wound significantly increased by albumin addition and it was concluded that intravenous albumin administration enhanced incisional wound healing in burned rats. Increased protein synthesis with concurrent myolysis and protein breakdown by albumin addition was observed during wound healing.Becaplermin gel represents an important therapeutic advance for diabetic neuropathic foot ulcers with adequate blood supply. Randomized controlled trials have shown that it is effective in increasing healing rates. However, this efficacy has not been translated to positive clinical experience, and the drug is not widely used. Clearly, further work is needed to clarify whether use of becaplermin is justified in everyday clinical practice. combination with other growth factors or by exploring alternative modes of drug delivery (Papanas N., et al.; Clinical interventions in aging. 2008 Jan 1;3(2):233-40.)The neurological disorders associated with insufficient copper in Menkes disease and an excess of copper in Wilson's disease are well established; however, recent evidence suggests that copper may also be involved in other disorders, such as Alzheimer's, angiogenesis, and prion diseases. The exact role of copper, however, is uncertain. Lee VE et al. (Journal of inorganic biochemistry. 2007 Nov 1;101(11-12):1707-18.) examine the role of copper and zinc in the formation of protein deposits and the chelation and removal of the metal ions to reverse the process. The bovine serum albumin (BSA) protein forms a precipitate after the addition of approximately 6 copper(II) atoms or 8 zinc(II) atoms. Other metal ions, such as Ca(II), Al(III), Ni(II), and Co(II), did not precipitate the BSA even when the metal ion to BSA ratios were in excess of 1000. The copper and zinc protein precipitates returned to solution after addition of the chelating agents, EDTA or tetrathiometallates [(MS(4)(2-)), where M=Mo, W]. List of relevant known prior art document: S.No. Patent No. Title Granted1 US5164367A Method of using copper(II) containing compounds to accelerate wound healing 1992-11-052 CN115382008A Preparation method of injectable hydrogel suitable for diabetes wound repair 2023-03-103 CN110433333A Metal organic framework / electrospinning fiber composite having NO and copper ion slow release synergistic reactions, and preparation method and application 2022-07-014 CN114732900A Albumin nanoparticles coupled with indocyanine green and oxaliplatin as well as preparation and application of albumin nanoparticles 2022-07-125 CN114699523A Nano material for light-enhanced chemotherapy and integrated tumor diagnosis and treatment as well as preparation method and application of nano material 2022-07-056 US10973933B2 Nanoparticles for diagnosis and treatment of tumors 2021-03-247 CN108478843A Medical dressing having copper-containing coating and preparation method thereof 2021-03-028 CN113817326A Multifunctional catechol hydrogel dressing as well as preparation method and application thereof 2021-12-219 CN112250887A Copper metal organic framework nanoparticle functionalized hydrogel, preparation method and application thereof 2019-03-2610 CN115501382A Slow-release hydrogel wound dressing and preparation method thereof 2022-12-23Traversal of the prior arts above indicates that, treatment of chronic wound remains a problem for a long time. A number of diverse treatment modalities has been practiced across the globe that include conventional medicines (antibiotics, and anti-inflammatory drugs), therapeutics loaded formulations like hydrogel, films, micro & nanoparticles, acellular skin graft, growth factor therapy, hyperbaric oxygen therapy, negative pressure therapy, herbal medicines, maggot therapy, and leech therapy. Recently, several formulations containing cell derived exosomes or stem cells are also tested for chronic wound healing. Among the aforementioned formulations, ECM proteins like collagen, fibronectin, fibrinogen etc has often been used alone or in combination. Few of them are available in the market too that includes Fibracol® Plus which is composed of 90% collagen and 10% alginate and Promogran™ made up of 55% collagen, 45% oxidized regenerated cellulose. On the other hand, a number growth factor based topical gels are also reported and presently going through clinical trial. A brief description of those formulations is presented below: Material Type Therapeutic Type ReferencesBecaplermin Gel (Regranex®) Carboxy methyl cellulose Growth factor: PDGF N. Papanas, E. Maltezos, Becaplermin gel in the treatment of diabetic neuro- pathic foot ulcers, Clin. Interv Aging 3 (2) (2008) 233.Topical EGF spray Not specified Growth Factor: EGF K.H. Park, S.H. Han, J.P. Hong, S.-.K. Han, D.-.H. Lee, B.S. Kim, J.H. Ahn, J.W. Lee, Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: a phase iii multicenter, double-blind, randomized, placebo-controlled trial, Diabetes Res. Clin. Pract. 142 (2018) 335–344.Granexin® Cellulose Peptide C.L. Grek, G. Prasad, V. Viswanathan, D.G. Armstrong, R.G. Gourdie, G.S. Ghat- nekar, Topical administration of a connexin43- based peptide augments healing of chronic neuropathic diabetic foot ulcers: a multicenter, randomized trial, Wound Repair Regen. 23 (2) (2015) 203–212.Vulnamin® gel: hyaluronic acid with amino acids Alginate Peptide R. Cassino, E. Ricci, Effectiveness of topical application of amino acids to chronic wounds: a prospective observational study,J. Wound Care 19 (1) (2010) 29–34.Major limitation of the existing products are (i) limited effectiveness and poor performance, (ii) uncertainty of healing (iii) high cost (because of the use of high value therapeutic molecules).Hence there is still a need for cost effective biodegradable, biocompatible formulation with superior healing property in less time with reproducibility.Objectives of the InventionThe primary objective of the present invention is to provide a composition comprising self-assembled structure comprising a d block bivalent metal ion, an NIR photosensitizer and serum albumin which would be NIR- Responsive photodynamic- angiogenic molecule particularly suitable for the treatment of chronic wound.Another objective of the present invention is to provide said composition wherein said ‘d’ block bivalent metal ion would be Cu+2, serum albumin would include bovine serum albumin or albumin of other origin with a minimum of 70% homology in amino acid sequence with bovine serum albumin and NIR photosensitizer would be Indocyanine green (ICG) or its derivatives which would kill the bacteria (including antibiotic resistant bacteria) under the exposure of NIR laser by generating reactive oxygen species.Another objective of the present invention is to provide said self-assembled composition wherein said ‘d’ block bivalent metal ion would be released from the self-assembled structure and will activate HIF-1? pathway which in turn will enhance the expression of cellular VEGF and subsequently lead to angiogenesis,Another objective of the present invention is to provide a method for fabrication of Cu+2 induced bovine serum albumin- ICG self-assembled structure wherein the preferred solvent for preparation would be water and preferred temperature for preparation would be at room temperature at 25°- 30°C. Another objective of the present invention is to provide said self-assembled structure which would be applied to the wounds including chronic wounds such as pressure ulcer, venus ulcer and diabetic foot ulcer by any of the formulations of type aqueous suspension, spray, gel, ointment and patches made through solvent casting, freeze–drying, electrospinning, and 3D printing including bioprinting.Another object of the present invention is to provide the photodynamic and angiogenic therapeutic formulation which can be used in various form like spreadable gel, spray, powder, ointment.Yet another object of the present invention is to provide the photodynamic and angiogenic therapeutic formulation which is effective against antibiotic resistant version and biofilms.Summary of Invention The basic aspect of the present invention is directed to a protein based multifunctional therapeutics suitable for chronic wound healing including diabetic foot ulcers (DFU) comprising:a self-assembled structure of ‘d’ block bivalent metal ion induced serum albumin and NIR photosensitizer complex having co-acting NIR responsive photodynamic and angiogenic wound healing capability.Another aspect of the present invention provides the multifunctional therapeutics wherein said Cu+2 is selected from ‘d’ block bivalent metal ions, bovine serum albumin is selected from albumin of different origin with a minimum of 70% homology in amino acid sequence with human serum albumin and said NIR photosensitizer is selected from Indocyanine green(ICG) or its derivatives.A further aspect of the present invention provides the multifunctional therapeutics wherein said Cu+2 ion induced self-assembled aggregates of serum albumin-ICG-Cu+2 complex is bindable with florescent probes including 8-anilino-1-naphthalenesulfonic acid (ANS), for fluorescing in hydrophobic pockets. Yet another aspect of the present invention provides the multifunctional therapeutics wherein said serum albumin-ICG-Cu (II) is present in molar ratio of 1:1:6.Still another aspect of the present invention provides The multifunctional therapeutics as claimed in anyone of claims 1-4 wherein said BSA-ICG-Cu(II) complexes are beads of 1-3 µm in diameter & string structure with irregular lengths with an average of 44-60 µmat 500 KX, with said BSA-ICG-Cu(II) exhibiting peaks at 737 nm and 805 nm with red shift and increase in intensity.A still further aspect of the present invention provides the multifunctional therapeutics adapted as a multifunctional formulation-based platform for wound / chronic wound healing facilitating one or more of the following:NIR responsive ROS generation and photodynamic killing of bacteria in wound milieu including antibiotic resistant bacteria;promoting angiogenesis through Cu+2 induced activation of HIF-1 alpha pathway and subsequent VEGF synthesis;increasing interstitial albumin content in wound site to ensure local supply of albumin. Another aspect of the present invention provides a process for manufacturing the protein based multifunctional therapeutics comprising the steps of:a) providing stock solutions of the sources of serum albumin, a ‘d’ block bivalent metal ion and NIR photosensitizer complex; and b) forming self-assembled aggregates therefrom to thereby obtain ‘d’ block bivalent metal ion induced serum albumin and NIR photosensitizer complex having co-acting NIR responsive photodynamic and angiogenic wound healing capability wherein the ‘d’ block bivalent metal ion is selected from Cu (II).Yet another aspect of the present invention provides the process comprising the steps of: a) preparing stock solutions of Bovine Serum Albumin, copper sulphate, ICG and ANS in Milli-Q water in dark and storing said ICG and ANS stock solution in dark at 4°C;b) adding BSA [0.1mM] to ICG [0.1mM] and then Cu (II) [0.6mM] in 1:1:6 molar ratio in the solution resulting in the formation of BSA-ICG-Cu(II) complex at room temperature ,at pH 7.2±?0.2;c) incubating the resultant solution for 5 minutes to 1 hr, preferably 1 hour under physiological conditions 37 °C, forming a ppt.;d) collecting and washing the ppt two times by centrifuging the complex at 10,000 to 12,000 rpm preferably 10,000 rpm for one minute.Brief discussion of the accompanying figuresFigure 1 illustrates Schematic representation of the synthesis of Cu+2 induced BSA-ICG complex.Figure 2: Scanning electron microscopy images of (A) BSA, (B) BSA-Cu(II),(C) BSA-ICG and (D) BSA-ICG-Cu(II).Figure 3: UV-VIS-NIR absorption spectra of free BSA, free ICG, free Cu (II), BSA-ICG, BSA- Cu (II), BSA-ICG-Cu (II) and ICG-Cu (II).Figure 4: Intrinsic fluorescence spectra of free BSA, free ICG, free Cu (II), BSA-ICG, BSA- Cu (II), BSA-ICG-Cu (II) and ICG-Cu (II).Figure 5: ANS Fluorescence spectra of free BSA, free ICG, free Cu (II), BSA-ICG, BSA-Cu (II), BSA-ICG-Cu (II) and ICG-Cu(II).Figure 6: Angiogenic parameters quantified with Angiogenesis Analyzer (ImageJ) on calcein-AM stained images; (a) Number of branches, (b) Number of nodes, (c) Number of master segments and (d) Number of junctions (E) Fluorescence micrographs of HUVEC cells treated with BSA- ICG-Cu (II), BSA-ICG and BSA-Cu (II) on 3D gel matrix.Figure 7: Human dermal fibroblast cells were treated with of BSA-ICG, BSA-Cu (II) and BSA-ICG-Cu(II): (A) ELISA analysis of VEGF Expression after 24 hours post treatment, (B) quantitative evaluation of cytotoxicity by MTT test (cell metabolism) after 24 hours, (C) Calcein-AM stained cell images after 24 hours treatment, (D) Fluorescence microscopy images of cells stained with TRITC phalloidin for actin filaments (red) and nuclei counterstained with DAPI (blue) after 24 hours, (E) Immunofluorescence detection of a-smooth muscle actin (a- SMA) after treatment of 7 days and (F) Analysis of cell migration by in vitro wound healing assay.Figure 8: Photographs of bacterial colonies formed in E. coli DH 5 Alpha and S. aureus treated using BSA-ICG-Cu (II) with or without NIR (808 nm, 0.33 W / cm2).Figure 9: Showing the specificity of BSA variant (top panel). Only one type of BSA as reported in the document is good to form the precipitate. Bottom panel: composition specific variation in excitation-emission hot spot.Description of the InventionThe proposed invention is a one-step preparation of Cu (II) induced BSA–ICG self-assemble complex in aqueous system at room temperature following green chemistry approach which is capable of generating reactive oxygen species under the exposure of NIR 808 nm LASER and in situ release of Cu (II) ions in a controlled manner. The proposed invention is designed and fit for the treatment of chronic wound including diabetic foot ulcers (DFUs) because of its ability: (i) to kill the bacteria (including antibiotic resistant bacteria) present in the wound milieu through ROS generated by the conjugated ICG under the exposure of 808nm laser;(ii) to induce angiogenesis through controlled release of Cu(II) in the wound milieu and subsequent activation of HIF-1? pathway which in turn will enhance the expression of cellular VEGF; and(iii) to compensate the low content of BSA in the wound milieu (as a consequence of hypo- albuminemia)The invention's core advancement is a triple-selective system:1. Material Selectivity: Fatty acid, globulin and protease free BSA enables stable ICG loading. Using any type of BSA does not result the desired assembled structure. The BSA variant used is Sigma Chemical Co. Catalog No. A7030. Key features include heat shock fractionation, and the product is protease-free, fatty acid-free, and essentially globulin-free.2. Metal Selectivity: Cu(II) (not Zn / Fe) enables angiogenesis + ROS modulation3. Process Selectivity: Sequential assembly prevents component degradation and achieve multifunctionality.Unexpected cooperativity: Cu²? doesn't compete with ICG for BSA binding sites but creates new ternary interfaces. No prior art suggests Cu(II) could enable simultaneous mild hyperthermia, ROS generation, and angiogenesisThe advancement according to the present invention is discussed in further detail in relation to the following non-limiting exemplary illustrations.Example 1: Method of Cu (II) induced BSA -ICG complex preparationBovine Serum Albumin (Fatty acid, globulin and protease free BSA) Copper sulphate (CuSO4, anhydrous powder, =99.99% trace metals basis), Indocyanine green (ICG), 8-anilino-1-naphthalenesulfonic acid (ANS), were purchased from Sigma Chemical Co. (St. Louis, USA) and used as received. Ultrapure Milli-Q water (18.2 MO) was used to prepare all samples.Stock solution of BSA, copper sulphate, ICG and ANS were prepared in Milli-Q water in dark. The ICG and ANS stock solution were stored in dark at 4°C. As shown in figure 1, for the preparation of BSA-ICG-Cu (II), firstly BSA [0.1mM] was added to ICG [0.1mM] and then Cu (II) [0.6mM] was added in 1:1:6 molar ratio. The introduction of Cu (II) into the solution results in the formation of BSA-ICG-Cu(II) complex at room temperature with pH 7.2±?0.2. The samples were then incubated for 1 hour to ensure adequate complexation under physiological conditions (37 °C). The precipitate of the sample was then collected and washed two times by centrifuging the complex at 10,000 rpm for one minute to remove any free BSA, ICG or Cu(II) present in the complex. It is important to maintain specific operating parameters, select BSA variant, the order of addition, molar ratios, and preparation conditions (solvent and temperature) for successful formation of the Cu(II)-induced BSA–ICG complex. Random addition of BSA, ICG and Cu (II) will not yield the desired complex. a)Importance of Specific Molar Ratios (1:1:6 - BSA: ICG: Cu²?):The complexation process is highly sensitive to the stoichiometric balance of the components. Deviations from the optimized 1:1:6 molar ratio result in incomplete or unstable complex formation. For instance, at lower Cu²? ratios (e.g., 1:1:1 or 1:1:3), no aggregation or weak aggregation was observed, and the solution remained mostly transparent, indicating insufficient complex formation. At excessive Cu²? levels (e.g., 1:1:10), there is a chance of dissociation of ICG from the complex. Moreover, excessive copper not only disrupts the structural uniformity of the complex but also poses cytotoxic risks during biological applications.b)Necessity of Ordered Addition:The sequence in which BSA (Bovine Serum Albumin), ICG (Indocyanine Green), and copper ions are combined significantly influences the resulting complexes' structure, binding efficiency, and physicochemical properties.i. When ICG is added to BSA before copper, ICG binds strongly to the hydrophobic pockets of BSA, primarily at Sudlow site 1 (domain IIA), forming a stable BSA-ICG complex. When copper ions are introduced after BSA-ICG complex formation, copper binds to available sites on BSA, including the N-terminal site and free cysteine residues. Outcome: This order typically results in a dense, visible precipitate (high turbidity), indicating efficient complex formation. The binding of ICG first may stabilize certain BSA conformations, influencing how copper interacts with the protein-ligand complex.ii. However, following a reverse addition protocol i.e. adding BSA, then copper, then ICG results in BSA-copper complex formation first which immediately got precipitated. This induces protein conformational change that may prevent desired binding of ICG.c) Influence of Solvent and Temperature:Water (Milli-Q) as the solvent and room temperature (25–30 °C) are critical for preserving the structural integrity of BSA and its binding pockets. Higher temperature cannot be used as it denatures the protein and lower temperature slowed down the kinetics. pH is very important. It was observed that lower pH disrupts the complex formation. The process is conducted at pH 7.2±?0.2, which is critical for maintaining BSA structure and optimal complex formation; deviation from select pH results in unstable product.d) Failure of "Obvious" Alternativesi. ICG + Cu²? (no BSA) Instant ICG degradation (no PDT)ii. BSA + ICG (no Cu²?) Not much angiogenesis iii.Physical mixture (BSA+ICG+Cu) Phase separation (no molecular assembly)The successful formation of the BSA–ICG–Cu(II) self-assembled complex with the desired properties relies on strictly controlled operating parameters, including the type of BSA selected, Cu(II) as the divalent metal , specific order of addition, defined molar ratio of the three actives, temperature,pH. Deviation from these select conditions results in non-functional or unstable assemblies. Mere physical admixture of the three actives does not result in the desired assembled structure. Example 2: Characterization of Cu (II) induced BSA -ICG complexScanning electron microscopy images (SEM): In figure 2(A-D), represents SEM images of free BSA, BSA-Cu (II), BSA-ICG and BSA-ICG-Cu(II) respectively. As shown in the SEM image of figure 2(D), the obtained BSA-ICG-Cu(II) complex exhibits bead& string structure at 500 KX. Many beads like structures were found with 1-3 µm in diameter and strings were found with irregular lengths with an average of 44-60 µm while in other images figure 2 (A-C) such structures were not observed.UV-VIS-NIR Spectroscopy: The absorbance spectra of the samples were measured using a Shimadzu UV-1900i UV–vis spectrophotometer. The UV-VIS-NIR spectra of all the samples were recorded in the 190–1100 nm wavelength region. Ultrapure Milli-Q water was used as the blank as the samples were prepared in it. Quartz cuvettes having 1 cm optical pathlength were used. Measuring UV-vis absorption is an elementary method to get insight into structubral changes and gain an understanding of complex development.In figure 3, widely reported in literature, free ICG gives characteristic absorption peak in Milli Q water in the range of 713 nm and ~778 nm. Free BSA possessed two absorption peaks at 220 nm and 280 nm. The strong absorption peak at around 220 nm reflected the absorption of the backbone of BSA, while the weak absorption peak at around 280 nm resulted from the aromatic amino acids (Trp, Tyr, and Phe). BSA and ICG bind and give absorption peaks at 737nm, and 805 nm, showing a red shift and with a very little increase in intensity. BSA and Cu(II) form self-assembled complex complexes however does not provide any peak, while BSA-ICG-Cu(II) exhibit peaks at 737nm and 805nm with red shift and increase in intensity.Fluorescence spectroscopy: The fluorescence emissions were recorded using a Jasco spectrofluorometer FP-8300. This spectrofluorometer uses a continuous output Xe arc lamp as the excitation source. The excitation and emission slit widths were kept as 2.5 nm respectively. The obtained spectra were analyzed using Origin software.Intrinsic fluorescence measurement: Fluorescence quenching technique was applied to investigate whether ICG interact with BSA. It is a powerful method to study interactions of several substances with protein which can reveal the accessibility of quenchers to albumin's fluorophore groups. In figure 4, BSA has a strong fluorescence emission with a peak at 340 nm at ?ex 280 nm, while ICG and Cu(II) were almost non- fluorescent at ?ex 280 nm (J. Li et al., 2017). It can be seen that fluorescence intensity of BSA decreased with ICG with a slight blue shift. BSA-Cu(II) also showed quenching as Cu(II) quenches. BSA-ICG-Cu(II) quenched significantly more and a blue shift is observed. Literature reports support that a shift in the emission spectrum to shorter wavelengths with a progressive increase in quencher concentrations is mainly attributed to the fluorescence quenching of Trp residues buried deep inside the protein’s hydrophobic core.Study of the surface hydrophobicity by ANS binding assay8-Anilino-1-naphthalenesulfonic acid (ANS) is used as a hydrophobic fluorescence probe due to its high intensity in hydrophobic environments, and also as a microenvironment probe because of its unique ability to exhibit peak shift and intensity change depending on the surrounding solvent environment. To determine whether hydrophobic regions are accessible of protein, the fluorescence intensity of ANS were measured. ANS is an extrinsic fluorophore which is weakly fluorescent in aqueous environment but fluoresces strongly (with a concurrent blue shift in its emission maximum from 515 to 475 nm) when located in a hydrophobic environment. In figure 5, BSA-ICG with ANS showed a decrease in intensity of fluorescence and BSA-Cu(II) and BSA-ICG-Cu(II) complexes with ANS show a significant quenching intensity due to inaccessibility of binding pockets to the protein.Angiogenic and wound healing potential of BSA-ICG-Cu(II) complex:A tubular network formation assay was performed to evaluate the BSA-ICG-Cu(II) angiogenic network triggering ability. This assay displayed that BSA-ICG-Cu(II) encouraged the development of more tubular network among the HUVEC cells.According to the micrograph, with BSA-ICG, angiogenic network formation was not properly developed and was marked by discontinuity and fragility in the network formation, however in BSA-Cu (II) continuous intense network formation was demonstrated with the HUVECs. This has also been evident by the Image J analysis of the fluorescence micrographs (figure 6 A-D). Figure 6 (E) said fluorescent micrographs clearly indicate that Cu (II) has promoted intense network formation with the HUVEC cells.For the tube formation assay, the number of nodes, junctions, segments and relative tube lengths were measured to evaluate the potential of the present formulation to induce tube formation.In the four groups including the control, BSA-ICG-Cu(II), BSA-Cu(II) and BSA-ICG , the numbers of nodes were 232 ±18.5, 252 ± 3.05, 129 ± 1.41, and 127.5 ± 9.19 respectively, the numbers of junctions were 58.33 ± 3.51, 75.33 ± 5, 45.33 ± 3.51 and 39 ± 2.82, the numbers of branches were 61 ± 5.65, 89 ± 2.82, 65.66 ± 3.21 and 56.5 ± 2.12, the total number of meshes were 21991.5 ± 330.21, 34788 ± 3070.25, 17774 ± 609.5 and 11570.5 ± 1956.56, and the total master segments were 2720.5 ± 53.03, 4477 ± 2.82, 2877.5 ± 190.21 and 225 ± 564.27 respectively. The same have been presented in tabular form below:Table Parameters Control BSA-ICG-Cu(II) BSA-Cu(II) BSA-ICGNumber of nodes 232 ±18.5 252 ± 3.05 129 ± 1.41 127.5 ± 9.19Number of junctions 58.33 ± 3.51 75.33 ± 5 45.33 ± 3.51 39 ± 2.82Number of branches 61 ± 5.65 89 ± 2.82, 65.66 ± 3.21 56.5 ± 2.12,No of Mesh 21991.5 ± 330.21 34788 ± 3070.25 17774 ± 609.5 11570.5 ± 1956.56Total master segment 2720.5 ± 53.03 4477 ± 2.82 2877.5 ± 190.21 225 ± 564.27In addition, the relative tube length, increased to approximately 1.25 times (um) in BSA-ICG-Cu (II) in comparison to control. Further, fluorescence micrograph image analysis showed that the number of nodes, number of junctions, number of branches, number of meshes and total master segments was found to be maximum in BSA-ICG-Cu(II) compared to control and other groups (the table above). Thus it was concluded that the present formulation can be used to provide vascularization.All the samples showed similar biocompatibility, this suggests that no adverse effect has been caused. Formation of the tubular network of endothelial cells is crucial for promoting angiogenesis in 3D constructs and yet difficult to achieve.Expression of VEGFVEGF functions as a growth factor for endothelial cells, is pivotal in stimulating angiogenesis, the process of new blood vessel formation. Any biomaterial which has the ability to stimulate the synthesis of VEGF within cells can act as a proangiogenic material. In the skin, copper stimulates dermal fibroblasts proliferation. Copper is required for the activation of hypoxia- inducible factor-1 (HIF-1), a major transcription factor regulating the expression of VEGF.Gérard et al. reported that Copper sulphate (CuSO4) stimulated angiogenesis and collagen deposition. Copper ions could stimulate the expression of various signaling factors which may advantageously favour the proliferation and extracellular matrix deposition of fibroblasts.For the present invention, BSA-ICG-Cu (II) showed a highest VEGF expression of 3-fold in human adult dermal fibroblasts (HADF) in comparison to the Tissue culture plate (TCP) (figure 7 A). Among all the samples, BSA-ICG-Cu (II) induced highest expression (2- 3-fold increase) followed by BSA-Cu (II) (1 fold increase), BSA-ICG showed least expression of VEGF, which was almost equivalent to the control. This data clearly implied that the presence of Cu (II) in formulation for (HADF) directly influenced the VEGF synthesis. The secreted VEGF from HADF cells in-turn enhanced the endothelial cell proliferation, migration and tube or blood vessel formation.Study of cell proliferation by MTT assayTo evaluate the cytotoxicity, human dermal fibroblast cells were incubated with BSA-ICG, BSA-Cu (II) and BSA-ICG-Cu (II) for 24 hr. The relative viabilities were determined by standard MTT assay. As shown in figure 7 (B), the as-prepared BSA-ICG-Cu(II) formulation is biocompatible and likely safe for in vitro and in vivo studies.The biocompatibility of BSA-ICG-Cu (II) could be ascribed to the intrinsic biocompatibility of ICG and BSA. The ICG has been in clinic for more than ten years with confirmed safety and the albumin is a composition of blood with high biocompatibility. Thus, the formulation that prepared from these two materials inherits their biocompatibility and safety.Expression of alpha SMAThe phenotypic changes in Human dermal fibroblasts were identified using a-Smooth muscle actin (a-SMA) as a marker for a subset of activated fibrogenic cells, ie myofibroblasts, which are regarded as important effector cells of tissue fibrogenesis, a hallmark for myofibroblasts. As shown in Figure 7 (E), the BSA-ICG-Cu (II) complex groups show the stronger positive expression of a-SMA, comparing with the other control.Differentiated myofibroblasts are characterized by the expression of a-SMA. After 7 days, HADF cells seeded on glass coverslips were stained for a-SMA. Compared with the control group, there were more a-SMA in formulation BSA-ICG-Cu(II) treated groupsTogether, these results indicate that BSA-ICG-Cu (II) accelerates skin wound healing by enhancing myofibroblast level and increasing wound contraction during the remodeling phase of the wound healing process.Study of cell viability of human adult dermal fibroblast cellsTo study BSA-ICG-Cu(II) formulation supported cell viability of HADF cells, it is useful to compare the morphology of cells when they are incubated in media with and without the formulation. Furthermore, human dermal fibroblast cells were incubated with BSA-ICG-Cu (II) for 24h. Then, the cells were stained with calcein-AM for the imaging of live cells by fluorescence microscope imaging. The fluorescence microscope images in figure 7 (C) clearly showed that BSA-ICG-Cu (II) formulation could maintain good cell viability. Calcein AM penetrates live cells due to its lipophilic nature, where intracellular esterase cleaves it, liberating green fluorescent calcein, facilitating real-time imaging of live cells dynamics and viability with fluorescence microscopy.Typical fluorescence micrographs of HADF are shown in figure 7(D). The F-actin microfilaments appear red (phalloidin conjugate), while the DNA is stained blue (DAPI). The images show cells are randomly oriented after incubation in either medium, but there is no change in morphology of the cells when exposed to BSA-ICG-Cu (II) suggesting the formulation supports in cell viability.In-vitro wound healing assay: Cell migration is critical for the wound healing process. The wound healing potential of BSA- ICG-Cu (II) was investigated by evaluating the ability of the compounds to induce HDFB cell migration in comparison to the control using a scratch assay in figure 7 (F). The results were determined by measuring the cell-free areas of the cell monolayer after exposure to the treatments for 24 h. In the treated sample, the migratory cells almost covered the wound after 24 h whereas for the control sample, the migratory cells did not cover the entire wound after 24 h.In vitro antibacterial assayBased on the superior characteristics of BSA-ICG-Cu (II), the in vitro antibacterial activity of BSA-ICG-Cu (II) was investigated. The antibacterial effects of ICG, BSA-ICG, BSA-ICG-Cu (II) were assessed by a standard broth microdilution method. After being incubated for 2 hours with the samples, Staphylococcus aureus and Escherichia coli were treated with or without 808 nm NIR irradiation. Due to photothermal and photodynamic effects of ICG along with sustained release and agglomeration of protein, the antibacterial activity of BSA-ICG-Cu (II) was better than ICG and BSA-ICG. Notably the BSA-ICG-Cu (II) at a 4x concentration-100ul from the sample, after pulsed NIR irradiation of 15mins at 0.33 W / Cm2 the percentage increase in bactericidal efficacy of S. aureus was 6.35 ± 1.20, 10.8 ± 1.69, and 30.45 ± 1.20 while in E.coli was 5.8 ±2.5, 27.4 ±2.3, 47.4 ±6.18 after one, two and three hour consequently. After 3 hours, the microbes were plated on agar plates at 10 8 CFU / ml as shown in figure 8. It suggests that hyperthermia therapy (450C) with BSA-ICG-Cu (II) can inhibit the proliferation of E. coli and S. aureus.Surprising Technical AdvancementThe invention achieves controlled mild hyperthermia (40-42°C) with simultaneous high ROS generation under NIR exposure, which is critical for killing bacteria without damaging dermal cells (unlike conventional ICG that causes uncontrolled heating >50°C). This precise thermal control arises only from the ternary BSA-ICG-Cu(II) complex, where BSA acts as a thermal buffer and Cu(II) optimizes ICG's photophysics. Individual components (ICG alone or BSA-ICG) cannot achieve this balance.Skilled artisans would expect Cu²? to displace ICG from BSA (due to stronger BSA-Cu binding) or cause aggregation. Instead, in the present invention Cu²? acts as a molecular bridge surprisingly creating a stable ternary complex where all components retain functionality – a result contradicting established protein-dye-metal interaction principles.Critical Selectivity Parameters1. Metal Ion Specificityo Cu(II) enables stable assembly with dual functionality (angiogenesis + enhancement of ROS generation with ICG)o Other group d metals (Fe³?, Mn²?) quench ICG fluorescence and doesn’t form precipitate2. Specific BSA variant: A specially purified variant of bovine serum albumin (BSA) that is free from fatty acids, proteases, and globulins has been used. This selection was based on extensive experimental screening and careful design selection, which would not be apparent or achievable through a generic approach by a skilled person in the field. The use of this highly specific variant of BSA is critical to the success of our formulation and represents a unique aspect and key differentiator (USP) of our invention.3. Hyperthermia Control Mechanism at 0.3 W / cm2 laser powerWithout Cu (II): ICG + NIR ? ?T >50°C (cell death) With ternary complex: ?T = 41±0.5°C (ROS + mild heat)Favorable attributes of the BSA-ICG-Cu (II) obtained in accordance to the present invention:1. A single formulation capable of ensuring 3 different types of therapeutic actions simultaneously that include (i) killing of microbes (ii) formation of new blood vessel (iii) increasing interstitial albumin content.Topical application of BSA (bovine serum albumin) helps increasing albumin levels in the wound area, which is especially beneficial for patients with hypoalbuminemia. Studies have shown that albumin-loaded dressings significantly improve wound closure rates and promote tissue regeneration by supporting cell growth and reducing inflammation. These effects make BSA an effective topical agent for enhancing wound healing in chronic and complex wounds. (Purohit, S. S., 2023; ACS Applied Bio Materials, 6(12), 5531–5540). 2. Effective against antibiotic resistant version and biofilms.3. On-demand therapeutic response: Since the formulation is NIR responsive, the therapeutic response can be generated by exposing the formulation to NIR (808nm) laser.4. The formulation can be used in various form like spreadable gel, spray, powder, ointment etc.5. Biocompatible and biodegradable.6. Easy, inexpensive and environment friendly preparation.Thus, the present invention enables successful preparation of Copper (II) ion induced bovine serum albumin (BSA)-Indocyanine green(ICG) molecular self-assembly by a one-step preparation in aqueous system at room temperature following green chemistry approach as a photodynamic- angiogenic multifunctional therapeutic formulation for the chronic wound healing such as diabetic foot ulcer. The proposed invention is a 3-in-1 solution capable of (i) killing bacteria present in the wound milieu by photodynamic effect, (ii) ensuring new blood vessel formation and (iii) increasing the interstitial albumin content.

Claims

,CLAIMS:WE CLAIM:1.A protein based multifunctional therapeutics suitable for chronic wound healing including diabetic foot ulcers (DFU) comprising:a self-assembled structure of ‘d’ block bivalent metal ion induced serum albumin and NIR photosensitizer complex having co-acting NIR responsive photodynamic and angiogenic wound healing capability.2.The multifunctional therapeutics as claimed in claim 1 wherein said Cu+2 is selected from ‘d’ block bivalent metal ions, bovine serum albumin is selected from albumin of different origin with a minimum of 70% homology in amino acid sequence with human serum albumin and said NIR photosensitizer is selected from Indocyanine green(ICG) or its derivatives.

3. The multifunctional therapeutics as claimed in any one of claims 1 or 2 wherein said Cu+2 ion induced self-assembled aggregates of serum albumin-ICG-Cu+2 complex is bindable with florescent probes including 8-anilino-1-naphthalenesulfonic acid (ANS), for fluorescing in hydrophobic pockets.

4. The multifunctional therapeutics as claimed in anyone of claims 1-3 wherein said serum albumin-ICG-Cu (II) is present in molar ratio of 1:1:6.

5. The multifunctional therapeutics as claimed in anyone of claims 1-4 wherein said BSA-ICG-Cu(II) complexes are beads of 1-3 µm in diameter & string structure with irregular lengths with an average of 44-60 µmat 500 KX, with said BSA-ICG-Cu(II) exhibiting peaks at 737 nm and 805 nm with red shift and increase in intensity.

6. The multifunctional therapeutics as claimed in anyone of claims 1-5 adapted as a multifunctional formulation-based platform for wound / chronic wound healing facilitating one or more of the following:NIR responsive ROS generation and photodynamic killing of bacteria in wound milieu including antibiotic resistant bacteria;promoting angiogenesis through Cu+2 induced activation of HIF-1 alpha pathway and subsequent VEGF synthesis;increasing interstitial albumin content in wound site to ensure local supply of albumin.

7. A process for manufacturing the protein based multifunctional therapeutics as claimed in any one of claims 1-6 comprising the steps of:a) providing stock solutions of the sources of serum albumin, a ‘d’ block bivalent metal ion and NIR photosensitizer complex; and b) forming self-assembled aggregates therefrom to thereby obtain ‘d’ block bivalent metal ion induced serum albumin and NIR photosensitizer complex having co-acting NIR responsive photodynamic and angiogenic wound healing capability wherein the ‘d’ block bivalent metal ion is selected from Cu (II).

8. The process as claimed in claim 7 comprising the steps of: a) preparing stock solutions of Bovine Serum Albumin, copper sulphate, ICG and ANS in Milli-Q water in dark and storing said ICG and ANS stock solution in dark at 4°C;b) adding BSA [0.1mM] to ICG [0.1mM] and then Cu (II) [0.6mM] in 1:1:6 molar ratio in the solution resulting in the formation of BSA-ICG-Cu(II) complex at room temperature ,at pH 7.2±?0.2;c) incubating the resultant solution for 5 minutes to 1 hr, preferably 1 hour under physiological conditions 37 °C, forming a ppt.;d) collecting and washing the ppt two times by centrifuging the complex at 10,000 to 12,000 rpm preferably 10,000 rpm for one minute.Dated this the 3rd day of July, 2025 Anjan Sen Of Anjan Sen & Associates (Applicants Agent) IN / PA-199